Filing Details
- Accession Number:
- 0001477932-25-000517
- Form Type:
- 13D Filing
- Publication Date:
- 2025-01-28 19:00:00
- Filed By:
- Siokas Grigorios
- Company:
- Cosmos Health Inc. (PINK:COSM)
- Filing Date:
- 2025-01-29
- SEC Url:
- 13D Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Siokas Grigorios | 4,203,689 | 0 | 4,203,689 | 0 | 4,203,689 | 17.0% |
Filing
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 3)
|
Cosmos Health Inc. (Name of Issuer) |
Common Stock, Par Value $0.001 per share (Title of Class of Securities) |
221413206 (CUSIP Number) |
Elliot H. Lutzker 605 Third Ave, 34th Floor New York, NY, 10158 646-428-3210 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
01/14/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 221413206 |
| 1 |
Name of reporting person
Siokas Grigorios | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
 (a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
PF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
GREECE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
4,203,689.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
17.0 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Common Stock, Par Value $0.001 per share |
| (b) | Name of Issuer:
Cosmos Health Inc. |
| (c) | Address of Issuer's Principal Executive Offices:
5 AGIOU GEORGIOU, PILEA, 5 AGIOU GEORGIOU, PILEA, THESSALONIKI,
GREECE
, 55438. |
| Item 2. | Identity and Background |
| (a) | Grigorios Siokas |
| (b) | 5AG Georgiou Str., Pilea, Thessaloniki J3TK 57001 |
| (c) | CEO, Cosmos Health, Inc., 141 West Jackson Boulevard, Suite 4236, Chicago, IL 60604 |
| (d) | No criminal proceedings to be disclosed |
| (e) | No civil proceedings to be disclosed |
| (f) | Greece |
| Item 3. | Source and Amount of Funds or Other Consideration |
Personal funds, none of which have been borrowed. | |
| Item 4. | Purpose of Transaction |
There are no plans or proposals which the reporting person has which may result in any of the matters listed. | |
| Item 5. | Interest in Securities of the Issuer |
| (a) | 4,203,689 (17%) shares based on 24,032,040 shares issued and outstanding on January 14, 2025. |
| (b) | Sole voting power and disposition power - 4,203,689 shares; includes 3,491,306 issued shares; 212,383 shares issuable upon exercise of Exchange Warrants issued on October 20, 2022, pursuant to a Warrant Exchange Agreement dated as of October 3, 2022; and 500,000 shares issuable upon exercise of Series B Common Warrants exercisable at $3.00 per share sold pursuant to Registration Statement No. 333-267917. |
| (c) | On December 20, 2024, Mr. Siokas entered into a Debt Exchange Agreement pursuant to which he acquired 257,334 shares of common stock at an Exchange Rate of $0.5829 per share, or an aggregate of approximately $150,000, the fair market value of the Common Shares, in exchange for $150,000 the Company owed Mr. Siokas.
On January 13, 2025, Mr. Siokas entered into a Debt Exchange Agreement pursuant to which he acquired 163,666 shares of common stock at an Exchange Rate of $0.611 per share, or an aggregate of approximately $100,000, the fair market value of the Common Shares, in exchange for $100,000 the Company owed Mr. Siokas.
On January 14, 2025, Mr. Siokas entered into a Debt Exchange Agreement pursuant to which he acquired 87,247 shares of Common Stock at an Exchange Rate of $0.6877 per share, or an aggregate of approximately $60,000, the fair market value of the Common Shares, in exchange for $60,000 the Company owed Mr. Siokas.
On January 15, 2025, Mr. Siokas entered into a Debt Exchange Agreement pursuant to which he acquired 62,500 shares of Common Stock at an Exchange Rate of $0.80 per share, or an aggregate of approximately $50,000, the fair market value of the Common Shares, in exchange for $50,000 the Company owed Mr. Siokas.
On January 16, 2025 Mr. Siokas entered into a Debt Exchange Agreement pursuant to which he acquired 47,904 shares of common stock at an Exchange Rate of $0.835 per share, or an aggregate of approximately $40,000, the fair market value of the Common Shares, in exchange for $40,000 the Company owed Mr. Siokas.
On January 17, 2025, Mr. Siokas entered into a Debt Exchange Agreement pursuant to which he acquired 29,158 shares of Common Stock at an Exchange Rate of $0.8574 per share, or an aggregate of approximately $25,000, the fair market value of the Common Shares, in exchange for $25,000 the Company owed Mr. Siokas.
On January 22, 2025, Mr. Siokas entered into a Debt Exchange Agreement pursuant to which he acquired 38,900 shares of Common Stock at an Exchange Rate of $0.7712 per share, or an aggregate of approximately $30,000, the fair market value of the Common Shares, in exchange for $30,000 the Company owed Mr. Siokas. |
| (d) | No person has the right to receive, or the power to direct the receipt of dividends from, or proceeds from, the sale of such securities. |
| (e) | Not applicable. |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
None | |
| Item 7. | Material to be Filed as Exhibits. |
None |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|